太龍藥業(600222.SH)再次漲停:雙黃連口服液系列產品2018年營收佔比17.36%
格隆匯2月4日丨太龍藥業(600222.SH)公佈,公司股票交易於2020年1月22日、1月23日、2月3日連續3個交易日內日收盤價格漲幅偏離值累計超過20%,公司已於2020年2月4日披露了《公司股票交易異常波動公告》(公告編號:2020-005)。2020年2月4日公司股票再次漲停。
截至2020年2月4日,公司動態市盈率為87.4(公司2018年度虧損,經查詢中證指數有限公司官網無公司靜態市盈率、滾動市盈率數據);根據證監會行業分類結果,公司所處“醫藥製造”行業的靜態市盈率為35.51,滾動市盈率為34.55;公司當前市盈率水平高於同行業的平均水平。
公司近期經營情況正常,內外部經營環境未發生重大變化。公司雙黃連口服液系列產品2018年度營業收入佔收入總額的比例為17.36%,2019年1-3季度營業收入佔收入總額的比例為20.35%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.